Apr 25, 2017 - Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.
Apr 25, 2017 - Without price increases or deals to boost earnings, the pharmaceuticals sector faces a weak earnings season.
Apr 24, 2017 - Allergan, Express Scripts, and Vertex stocks look attractive in a generally overpriced market.
Apr 23, 2017 - Gilead Sciences might want to pay attention to Allergan's aggressive expansion of its NASH program.
Apr 19, 2017 - Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis
Apr 18, 2017 - Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.
Apr 13, 2017 - Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.
Mar 31, 2017 - Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
Mar 30, 2017 - Investors interested in maintaining a diversified portfolio might consider investing in equal-weight funds.
Mar 28, 2017 - Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline